Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. on October 28, 2022. The report discloses corporate governance changes, specifically the appointment of a new Chief Financial Officer. Note: The request metadata references "Chronoscale Holdings Corp," but the filing text explicitly identifies the registrant as Ekso Bionics Holdings, Inc.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Jerome Wong as Chief Financial Officer, Corporate Secretary, and Principal Financial Officer, effective October 26, 2022. Mr. Wong transitions from an interim role held since June 2022 to a permanent position.
Management Commentary and Compensation Details
- Base Salary: $325,000 annually.
- Bonus Eligibility: Up to 50% of base salary contingent on company and individual performance milestones.
- Equity Award: $250,000 in restricted stock units (RSUs) vesting over three years under the 2014 Equity Incentive Plan.
- Severance: Six months of salary continuation if terminated without cause.
- Other Benefits: Eligible for standard health insurance and employee benefit plans.
The filing states there are no undisclosed arrangements or family relationships influencing the appointment.
Investor Verification Checklist
- Verify the exact vesting schedule and performance conditions for the $250,000 RSU award in the full Offer Letter (Exhibit 10.1).
- Review the standard officer indemnification agreement referenced in the filing to understand liability protections.
- Confirm the company's current cash position to assess the impact of the new executive compensation package on liquidity.
- Check subsequent filings for any changes to the interim financial reporting status during the transition period.